Islet Cell Transplant After Kidney Transplant in Type 1 Diabetes
Tests islet cell transplants in adults with type 1 diabetes and a kidney transplant.
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Registry title
- Islet Transplantation in Type 1 Diabetic Kidney Allograft
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 10 people, planned
- Started
- Dec 2010
- Expected to end
- Dec 2026
- Type of study
- Interventional
- Treatments tested
- Allogenic islet cells (human, U. Chicago)
- Intraportal infusion of islet cells
- Record updated
- 8 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes who have a kidney transplant. It tests the safety of islet cell transplantation after the kidney transplant.
- Age
- 18 to 68 years
- Sex
- Women and men
- Disease stage
- Type 1 diabetes that started before age 40, with insulin use for more than 5 years. The body makes no insulin of its own (stimulated c-peptide below 0.3 ng/mL). Kidney function must be stable.
- Earlier treatment
- At least 3 months after a kidney transplant on standard immunosuppression (calcineurin inhibitor based), or islets given within 72 hours after the kidney transplant from the same donor.
- Biomarker or test result
- Stimulated c-peptide below 0.3 ng/mL after a mixed-meal test. Panel-reactive anti-HLA antibodies above 50% lead to exclusion if certain other antibody findings are present.
Main reasons for not taking part
- Weight over 90 kg (198 lb) or BMI over 30 kg/m2
- Other organ transplants, apart from the kidney (one specific failed pancreas graft is allowed)
- Active infection, including hepatitis B, hepatitis C, HIV or tuberculosis
- Pregnancy, breast-feeding, or plans to have a child during the study or within 4 months after it
- Blood pressure above 160/100 mmHg despite treatment, or untreated proliferative diabetic retinopathy
This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: Subjects who are > or at 3 months post-renal transplant who are taking appropriate calcineurin inhibitor (CNI) based maintenance immunosuppression ([tacrolimus alone or in conjunction with sirolimus, mycophenolate mofetil, myfortic, or azathioprine; or cyclosporine in conjunction with sirolimus, mycophenolate mofetil, or myfortic] ± Prednisone < 10 mg/day)or subject will receive islets transplant within 72hours after kidney transplantation (islets and kidney are from the same donor)
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Male and female subjects age 18 to 68 years
- Subjects who are able to provide written informed consent and to comply with the procedures of the study protocol
- Clinical history compatible with T1D with disease onset < 40 years of age and insulin-dependence for > 5 years at the time of enrollment, and a sum of subject age and insulin dependent diabetes duration of > 28
- Absent stimulated c-peptide (< 0.3 ng/mL) in response to a MMTT [Boost® 6 mL/kg body weight (BW) to a maximum of 360 mL; another product with equivalent caloric and nutrient content may be substituted for Boost®] measured at 60 and 90 min after start of consumption
- Subjects who are > or at 3 months post-renal transplant who are taking appropriate calcineurin inhibitor (CNI) based maintenance immunosuppression ([tacrolimus alone or in conjunction with sirolimus, mycophenolate mofetil, myfortic, or azathioprine; or cyclosporine in conjunction with sirolimus, mycophenolate mofetil, or myfortic] ± Prednisone < 10 mg/day)or subject will receive islets transplant within 72hours after kidney transplantation (islets and kidney are from the same donor)
- Stable renal function as defined by a creatinine of no more than one third greater than the average creatinine determination performed in the 3 previous months prior to islet transplantation, until rejection, obstruction or infection is ruled out
Who cannot take part
- Other (non-kidney) organ transplants except prior failed pancreatic graft where the graft failed within the first two weeks due to thrombosis, followed by pancreatectomy; with the pancreas transplant occurring more than 6 months prior to enrollment
- Blood Pressure: SBP > 160 mmHg or DBP >100 mmHg despite treatment with antihypertensive agents
- Either Class I or Class II panel-reactive anti-HLA antibodies > 50%. Subjects with either Class I or Class II panel reactive anti-HLA antibodies >50% will be excluded if any of the following are detected: Positive cross-match, Islet donor-directed anti-HLA antibodies detected by Luminex Single Antigen/specificity bead assay including weakly reactive antibodies that would not be detected by a flow cross-match, or Antibodies to the renal donor (i.e. presumed de novo)
- Calculated GFR < 40 mL/min/1.73 m2 using the subject's measured serum creatinine and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [1]. Strict vegetarians (vegans) will be excluded only if their estimated GFR is < 35 mL/min/1.73 m2
- Proteinuria (albumin/ creatinine ratio or ACr > 300mg/g) of new onset since kidney transplantation
- Presence or history of active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB). Subjects with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection
- Weight more than 90 kg or body mass index (BMI) > 30 kg/m2
- Insulin requirement of >1.0 IU/kg/day or <15 U/day
- Untreated or unstable proliferative diabetic retinopathy
- For female subjects: Positive pregnancy test, presently breast-feeding, desires to be pregnant at any time point in the future, which includes during or after the completion of the study even if study participation is ended early, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 68 years old?
Where in United States
- The University Of ChicagoChicago, United StatesContact: Lindsay Basto, RN, BSNTaking people
About the trial
What the trial wants to find out
The purpose of this study is to learn about the safety of islet transplantation when performed after kidney transplantation, which may provide more normal control of blood sugar without the need for insulin shots. Islets are special clusters of cells within the pancreas that produce insulin. These cells will be obtained from cadaver (non-living) donors and given to subjects by vein.
The group in the trial
- Allogenic islet cells (human, U. Chicago)Treatment being tested
Treatment: Allogenic islet cells (human, U. Chicago) and Intraportal infusion of islet cells
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Islet Transplantation in Type 1 Diabetic Kidney Allograft
- Plain-language title
- Islet Cell Transplant After Kidney Transplant in Type 1 DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT01241864, who can take part
- Record updated
- 8 December 2025